Everest Medicines to Announce Full-Year 2022 Financial Results on March 31, 2023
SHANGHAI, March 15, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced that it will report financial results for the full year ended December 31, 2022 and provide a business update on March 31, 2023. The Company will hold live conference calls in English...
Over 1,000 Patients Enrolled in Landmark SELUTION DeNovo Study
GENEVA, March 15, 2023 /PRNewswire/ -- MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo coronary randomized study. Recruitment is now a third of the way towards the target of 3,326 patients. SELUTION DeNovo compares the treatment strategy using a novel sirolimus drug-eluting balloon , versus a limus drug-eluting...
HanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship Program
Applications for physicians trained in Indonesia now open until April 15, 2023 12:00 AM The Pharmaceutical Industry Fellowship Program provides physicians with the opportunity to experience the various steps of the drug development process ROCKVILLE, Md. and SEOUL, South Korea, March 15, 2023 /PRNewswire/ -- HanAll Biopharma Co., Ltd. (KRX:...
Hummingbird Bioscience to Present Two Posters on HER3-Targeting Therapeutics at American Association for Cancer Research (AACR) Meeting 2023
Presentations highlight the robust tumor growth inhibition in preclinical models for its HER3-targeting programs HMBD-001 (HER3 mAb) and HMBD-501 (HER3 ADC) HMBD-001 used as monotherapy or in combination with cetuximab effectively inhibits tumor growth in preclinical squamous cell carcinoma models HMBD-501 shows superior preclinical efficacy and tolerability compared to other HER3...
SAP Introduces SAP Datasphere to Simplify Customers’ Data Landscape
HONG KONG, March 15, 2023 /PRNewswire/ -- SAP SE (NYSE: SAP) has announced key data innovations and partnerships that give customers access to mission-critical data, enabling faster time to insights and better business decision-making. SAP announced the SAP Datasphere solution, the next generation of its data management portfolio, which gives customers easy access to business-ready data across the data landscape....
Nippon Express (Belgium) Joins Pharma.Aero
TOKYO, March 15, 2023 /PRNewswire/ -- Nippon Express (Belgium) N.V./S.A. (hereinafter "NX Belgium"), a group company of NIPPON EXPRESS HOLDINGS, INC., became the first Japanese forwarder to join Pharma.Aero (*) on January 25 this year. Pharma.Aero logo: https://kyodonewsprwire.jp/img/202303033576-O1-98z3VY1t NIPPON EXPRESS logo: https://kyodonewsprwire.jp/img/202303033576-O2-Liv03U6J The Nippon Express Group has positioned the pharmaceutical industry as a key industry in its "Nippon Express...
Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting
BEIJING and SHANGHAI and BOSTON, Mass., March 15, 2023 /PRNewswire/ -- Jacobin Pharma (1167.HK) today announced that the company will present the results of three preclinical studies of KRASmulti inhibitor JAB-23425, CD73-STING iADC JAB-X1800, and Aurora kinase A inhibitor JAB-2485 in form of the abstract during the American Association for Cancer Research (AACR) Annual Meeting...
Alphamab Oncology to Present the Preclinical Results of PD-L1/OX40 Bispecific Antibody KN052 at AACR 2023
SUZHOU, China, March 15, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the preclinical result of KN052 (PD-L1/OX40 bispecific antibody) is accepted as Late-Breaking Research in 114th Annual Meeting of the American Association for Cancer Research (AACR 2023). The results will be presented as poster(Abstract: LB021). The AACR Annual Meeting is the largest cancer meeting in the...
Illumina launches its first product enabling long- and short-read sequencing on one instrument
Early customer data reinforces accuracy and flexibility of novel long-read technology, unlocking access to challenging, low DNA input samples SAN DIEGO, March 15, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that its first product based on its novel Illumina Complete Long Read technology is now available to order. The...
Ascentage Pharma to Present Latest Results from Three Preclinical Studies at 2023 American Association for Cancer Research Annual Meeting
SUZHOU, China and ROCKVILLE, Md., March 15, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the latest results from three preclinical studies of the company's novel third-generation BCR-ABL inhibitor olverembatinib (HQP1351) and two key assets of...
